These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 39323022)

  • 1. Discovery of Novel PROTAC SIRT6 Degraders with Potent Efficacy against Hepatocellular Carcinoma.
    Huang J; Su J; Wang H; Chen J; Tian Y; Zhang J; Feng T; Di L; Lu X; Sheng H; Zhu Q; Chen X; Wang J; He X; Yerkinkazhina Y; Xie Z; Shu Y; Kang T; Tang H; Qian J; Zhu WG
    J Med Chem; 2024 Oct; 67(19):17319-17349. PubMed ID: 39323022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of Potent and Selective c-Met Degraders for Hepatocellular Carcinoma Treatment.
    Min W; Yang H; Wang D; Chen C; Wang Y; Hou Y; Zhu Y; Sun C; Wang X; Yuan K; Yang P
    J Med Chem; 2024 Jul; 67(14):12314-12330. PubMed ID: 38962837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sirtuin 6 promotes transforming growth factor-β1/H2O2/HOCl-mediated enhancement of hepatocellular carcinoma cell tumorigenicity by suppressing cellular senescence.
    Feng XX; Luo J; Liu M; Yan W; Zhou ZZ; Xia YJ; Tu W; Li PY; Feng ZH; Tian DA
    Cancer Sci; 2015 May; 106(5):559-66. PubMed ID: 25683165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a cellularly active SIRT6 allosteric activator.
    Huang Z; Zhao J; Deng W; Chen Y; Shang J; Song K; Zhang L; Wang C; Lu S; Yang X; He B; Min J; Hu H; Tan M; Xu J; Zhang Q; Zhong J; Sun X; Mao Z; Lin H; Xiao M; Chin YE; Jiang H; Xu Y; Chen G; Zhang J
    Nat Chem Biol; 2018 Dec; 14(12):1118-1126. PubMed ID: 30374165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti‑cancer effects of a novel Pan‑RAF inhibitor in a hepatocellular carcinoma cell line.
    Wang W; Xu B; Li Q; Jiang D; Yan S
    Mol Med Rep; 2018 Apr; 17(4):6185-6193. PubMed ID: 29484394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
    Chen B; Wei W; Ma L; Yang B; Gill RM; Chua MS; Butte AJ; So S
    Gastroenterology; 2017 Jun; 152(8):2022-2036. PubMed ID: 28284560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel STAT3 oligonucleotide compounds suppress tumor growth and overcome the acquired resistance to sorafenib in hepatocellular carcinoma.
    Zhang QY; Ding W; Mo JS; Ou-Yang SM; Lin ZY; Peng KR; Liu GP; Lu JJ; Yue PB; Lei JP; Wang YD; Zhang XL
    Acta Pharmacol Sin; 2024 Aug; 45(8):1701-1714. PubMed ID: 38609562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of 2,6-Naphthyridine Analogues as Selective FGFR4 Inhibitors for Hepatocellular Carcinoma.
    Oh H; Kim J; Jung SH; Ha TH; Ahn YG; Nam G; Moon K; Singh P; Kim IS
    J Med Chem; 2024 May; 67(10):8445-8459. PubMed ID: 38706130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, biological evaluation, and modeling studies of novel conformationally-restricted analogues of sorafenib as selective kinase-inhibitory antiproliferative agents against hepatocellular carcinoma cells.
    Sbenati RM; Zaraei SO; El-Gamal MI; Anbar HS; Tarazi H; Zoghbor MM; Mohamood NA; Khakpour MM; Zaher DM; Omar HA; Alach NN; Shehata MK; El-Gamal R
    Eur J Med Chem; 2021 Jan; 210():113081. PubMed ID: 33310290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sirt6 suppresses hepatocellular carcinoma cell growth via inhibiting the extracellular signal‑regulated kinase signaling pathway.
    Zhang ZG; Qin CY
    Mol Med Rep; 2014 Mar; 9(3):882-8. PubMed ID: 24366394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of a first-in-class protein degrader for the c-ros oncogene 1 (ROS1).
    Yang J; Wu Y; Zhu Q; Qu X; Ou H; Liu H; Wei Y; Ge D; Lu C; Jiang B; Song X
    Bioorg Chem; 2024 Sep; 150():107590. PubMed ID: 38955003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The combination of lonafarnib and sorafenib induces cyclin D1 degradation via ATG3-mediated autophagic flux in hepatocellular carcinoma cells.
    Wang J; Wei H; Huang Y; Chen D; Zeng G; Lian Y; Huang Y
    Aging (Albany NY); 2019 Aug; 11(15):5769-5785. PubMed ID: 31409760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SIRT6 Is a Target of Regulation by UBE3A That Contributes to Liver Tumorigenesis in an ANXA2-Dependent Manner.
    Kohli S; Bhardwaj A; Kumari R; Das S
    Cancer Res; 2018 Feb; 78(3):645-658. PubMed ID: 29217762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of penipanoid C-inspired 2-(3,4,5-trimethoxybenzoyl)quinazolin-4(3H)-one derivatives as potential anticancer agents by inhibiting cell proliferation and inducing apoptosis in hepatocellular carcinoma cells.
    Wang CJ; Guo X; Zhai RQ; Sun C; Xiao G; Chen J; Wei MY; Shao CL; Gu Y
    Eur J Med Chem; 2021 Nov; 224():113671. PubMed ID: 34237623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation of a Novel One-Armed Anti-c-Met Antibody with Antitumor Activity Against Hepatocellular Carcinoma.
    Yin Y; Guo J; Teng F; Yu L; Jiang Y; Xie K; Jiang M; Fang J
    Drug Des Devel Ther; 2019; 13():4173-4184. PubMed ID: 31849449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells.
    Wang L; Zhan Y; Wu Z; Lin M; Jin X; Jiang L; Qiu Y
    Biomed Pharmacother; 2020 May; 125():110033. PubMed ID: 32187962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TAK1 Is a Novel Target in Hepatocellular Carcinoma and Contributes to Sorafenib Resistance.
    Xia S; Ji L; Tao L; Pan Y; Lin Z; Wan Z; Pan H; Zhao J; Cai L; Xu J; Cai X
    Cell Mol Gastroenterol Hepatol; 2021; 12(3):1121-1143. PubMed ID: 33962073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [YAP regulates the proliferation and modifies the sensitivity to sorafenib in hepatocellular carcinoma cells].
    Guo LW; Shao GL; Luo J; Hao WY; Yao Z; Zheng JP
    Zhonghua Zhong Liu Za Zhi; 2018 Nov; 40(11):818-823. PubMed ID: 30481931
    [No Abstract]   [Full Text] [Related]  

  • 19. MDL-800, an allosteric activator of SIRT6, suppresses proliferation and enhances EGFR-TKIs therapy in non-small cell lung cancer.
    Shang JL; Ning SB; Chen YY; Chen TX; Zhang J
    Acta Pharmacol Sin; 2021 Jan; 42(1):120-131. PubMed ID: 32541922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model.
    Wang C; Gao D; Guo K; Kang X; Jiang K; Sun C; Li Y; Sun L; Shu H; Jin G; Sun H; Wu W; Liu Y
    BMC Cancer; 2012 May; 12():166. PubMed ID: 22559167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.